Bank of America Is Spending 13% of Its Healthcare Budget on GLP-1 Drugs

Bank of America now spends more than $250 million annually on GLP-1 drugs, forcing corporate America to weigh higher healthcare costs against the possibility of healthier employees and long-term savings.

Weight-loss drugs have become a multibillion-dollar business for pharmaceutical companies. For large employers, they are also becoming one of the fastest-growing items on the healthcare bill.

Bank of America now spends more than $250 million a year providing GLP-1 drugs to its employees, according to CEO Brian Moynihan. That represents approximately 13% of the bank’s entire $2 billion annual healthcare budget.

The figure is particularly striking because these medicines accounted for almost none of the company’s healthcare spending just four or five years ago. Demand has since accelerated as drugs such as Wegovy and Zepbound have moved beyond diabetes treatment and into the much larger obesity market.

With around 211,000 employees, Bank of America has the scale to negotiate directly with drugmakers over prices. It also combines access to GLP-1 treatments with coaching and other health programmes designed to help employees achieve longer-lasting results.

Moynihan believes the expense could eventually pay for itself. Obesity is connected to several costly long-term conditions, including cardiovascular disease. If the treatments improve employee health and reduce the need for other medical care, some of today’s spending could be recovered over time.

That argument remains difficult to prove, however. GLP-1 drugs can cost thousands of dollars per patient each year, and some users regain weight after stopping treatment. Employers must therefore decide whether they are funding a temporary prescription or making a long-term commitment.

Bank of America has chosen to maintain broad access, but many companies are taking a more cautious approach. Some have tightened eligibility requirements, introduced mandatory coaching or removed weight-loss coverage altogether as costs increased.

This creates a new challenge for corporate America. GLP-1 medicines may improve employee health, reduce absenteeism and make benefits packages more attractive, but they can also consume a significant portion of an employer’s healthcare budget before the long-term savings are clear.

Bank of America’s $250 million bill shows just how quickly the market has changed. Weight-loss drugs are no longer only a pharmaceutical success story. They are becoming a major financial decision for every large employer paying for them.